Emory Genetics Laboratory

The test, which EGL plans to launch clinically this summer, is designed to boost diagnostic yield by helping to resolve variants of unknown significance.

Emory and Eurofins, following their JV last year, plan to open several clinical genetics labs across the globe that draw on EGL's expertise.

In exome sequence data for individuals with limb-girdle muscular dystrophy, researchers identified individuals carrying more than one pathogenic mutation.

The new joint venture will be called EGL Genetic Diagnostics.

The Belgium-based testing firm believes acquiring the university laboratory will strengthen its position in specialty clinical diagnostic testing.

Emory's Madhuri Hegde presented two cases that illustrate how researchers can initially be led astray in their initial interpretation of exome data.

NEW YORK (GenomeWeb) — Oxford Gene Technology has launched a new microarray product that it believes will be attractive to medical research laboratories that use targeted, next-generation sequencing panels.

NEW YORK (GenomeWeb News) – Oxford Gene Technology said today that it has been working with Emory Genetics Laboratory to develop a menu of comparative genomic hybridization arrays focused on a variety of genetic disorders.

While ethnicity-based screening remains the consensus approach for identifying disease-causing mutations, the American population is becoming increasingly admixed, meaning that genetic laboratories often have to run multiple panels on the same individual.

In a first for next-generation sequencing, late last month, the US Food and Drug Administration cleared Illumina's MiSeqDx system along with three assays — two cystic fibrosis assays and a Universal Kit that includes the reagents for clinical labs to develop their own assays.

Pages

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.